Clinical Trials Directory

Trials / Unknown

UnknownNCT05734950

Biological Characteristics of Older Women (> 70 Years) With ER Positive, HER2 Negative Early Breast Cancer

Biological Characteristics of Older Women (> 70 Years) With Oestrogen-receptor (ER) Positive, Human Epidermal Growth Factor 2 (HER2) Negative Early Breast Cancer: Definition of Molecular and Genomic Features.

Status
Unknown
Phase
Study type
Observational
Enrollment
100 (estimated)
Sponsor
Royal Marsden NHS Foundation Trust · Academic / Other
Sex
Female
Age
71 Years
Healthy volunteers
Accepted

Summary

This study is investigating the biological characteristics of early oestrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer (BC) in older woman (aged \> 70 years) who were treated with adjuvant endocrine treatment (ET). It will use surgical tissue previously collected as part of routine care from patients aged 70 years or older at diagnosis with ER positive, HER2 negative stage I-III BC treated The Royal Marsden NHS Foundation Trust (RMH). The overarching aim of this study is to define the biological characteristics of early BC in older women in terms of tumour microenvironment (TME), molecular and genomic features. This analysis will include assessment of tumour infiltrating lymphocytes (TILs), and gene expression profiling with NanoString using the Breast Cancer 360 (BC360TM) assay measuring ribonucleic acid (RNA) expression signatures of genes involved in proliferation, endothelial, angiogenesis, cytotoxicity, stroma, inflammatory chemokines, and apoptosis. This analysis will examine various biological pathways, aiming to inform suitability for certain treatments including cyclin-dependent kinase inhibitors (CDKi), chemotherapy, immunotherapy, or targeted treatments such as phosphoinositide 3-kinases (PI3K) inhibitors, or deoxyribonucleic acid (DNA) damage response.

Conditions

Interventions

TypeNameDescription
OTHERTranslational studyNon-interventional, translational study

Timeline

Start date
2022-07-21
Primary completion
2023-08-31
Completion
2023-08-31
First posted
2023-02-21
Last updated
2023-02-21

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT05734950. Inclusion in this directory is not an endorsement.